RT Journal Article
SR Electronic
T1 The impact of same-day antiretroviral therapy initiation under the WHO Treat-All policy
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.04.20090068
DO 10.1101/2020.05.04.20090068
A1 Kerschberger, Bernhard
A1 Boulle, Andrew
A1 Kuwengwa, Rudo
A1 Ciglenecki, Iza
A1 Schomaker, Michael
YR 2020
UL http://medrxiv.org/content/early/2020/05/08/2020.05.04.20090068.abstract
AB Background The World Health Organization recommends rapid initiation of antiretroviral therapy (ART) for people living with HIV, with the option to start treatment on the day of diagnosis (same-day-ART). However, the effect of same-day-ART remains unknown in realistic public sector settings.Methods We established a cohort of ≥16-year-old patients who initiated first-line ART under Treat-All in Eswatini between 2014-2016, either on the day of HIV care enrolment (same-day-ART) or 1–14 days thereafter (early-ART). Directed acyclic graphs, flexible parametric survival analysis and targeted maximum likelihood estimation (TMLE) were used to estimate the effect of same-day ART initiation on the composite unfavourable treatment outcome (loss to follow-up;death;viral failure).Results Of 1328 patients, 839 (63.2%) initiated same-day ART. The adjusted hazard ratio of the unfavourable outcome was increased by 48% (95% CI:1.16–1.89) for same-day ART compared with early ART. TMLE suggested that after 1 year, 28.9% of patients would experience the unfavourable outcome under same-day ART compared with 21.2% under early ART (difference: 7.7%; 1.3–14.1%). This effect varied over time in regression analysis and TMLE, with a higher hazard during the first year after HIV care enrolment and a similar hazard thereafter.Conclusions Caution is needed in implementing same-day ART in routine settings.Competing Interest StatementThe authors have declared no competing interest.Funding Statement--Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe software code and data can be obtained from the authors. New analyses on the data require approval from the government of Eswatini and MSF.